McNally Thomas W, Damato Erika M, Murray Philip I, Denniston Alastair K, Barry Robert J
University of Birmingham Medical School, University of Birmingham, Birmingham, UK.
Behcet's Centre of Excellence, City Hospital, Sandwell & West Birmingham Hospitals NHS Trust, Birmingham, UK.
Orphanet J Rare Dis. 2017 Jul 17;12(1):130. doi: 10.1186/s13023-017-0681-6.
ᅟ: Behçet's disease (BD) is a systemic vasculitis characterised by a relapsing remitting course, affecting multiple organ systems. In the eye, it is a cause of potentially blinding inflammation in the form of uveitis. Management of uveitis in BD often requires the use of systemic immunosuppression, in order to reduce disease activity and prevent accumulation of irreversible damage. Whilst corticosteroids remain the mainstay of treatment, long-term use is limited by the development of adrenocorticotrophic side effects. There has therefore been significant interest in the use of corticosteroid-sparing immunosuppressive agents, and more recently, biologic therapies. Recent publications have demonstrated biologic therapy to have beneficial effects both on overall disease control, and quality of life for patients with BD. Widespread use of such agents is however limited, partly by the lack of high quality research evidence, and partly by the prohibitive cost of biologic treatments. In this review, we discuss the most recent research investigating the use of biologic therapy in uveitis due to BD, with consideration of health economics and quality of life outcomes.
白塞病（BD）是一种系统性血管炎，其特征为病情复发缓解，累及多个器官系统。在眼部，它是以葡萄膜炎形式导致潜在致盲性炎症的病因。BD患者葡萄膜炎的治疗通常需要使用全身免疫抑制，以降低疾病活动度并防止不可逆损伤的累积。虽然皮质类固醇仍然是主要治疗药物，但长期使用会受到促肾上腺皮质激素副作用的限制。因此，人们对使用能减少皮质类固醇用量的免疫抑制剂，以及最近对生物疗法产生了浓厚兴趣。最近的出版物表明，生物疗法对BD患者的整体疾病控制和生活质量都有有益影响。然而，此类药物的广泛使用受到限制，部分原因是缺乏高质量的研究证据，部分原因是生物治疗成本高昂。在本综述中，我们讨论了关于BD所致葡萄膜炎使用生物疗法的最新研究，并考虑了卫生经济学和生活质量结果。
